|
1
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura T, Matsumine A, Matsubara T,
Asamuma K, Niimi R, Uchida A and Sudo A: Retrospective analysis of
metastatic sarcoma patients. Oncol Lett. 2:315–318. 2011.PubMed/NCBI
|
|
5
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stenmark H: Rab GTPases as coordinators of
vesicle traffic. Nat Rev Mol Cell Biol. 10:513–525. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montalbano J, Jin W, Sheikh MS and Huang
Y: RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras
superfamily GTP-binding protein and is overexpressed in breast
cancer. J Biol Chem. 282:37640–37649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Montalbano J, Lui K, Sheikh MS and Huang
Y: Identification and characterization of RBEL1 subfamily of
GTPases in the Ras superfamily involved in cell growth regulation.
J Biol Chem. 284:18129–18142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hochegger H, Takeda S and Hunt T:
Cyclin-dependent kinases and cell-cycle transitions: Does one fit
all? Nat Rev Mol Cell Biol. 9:910–916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Classon M and Harlow E: The retinoblastoma
tumour suppressor in development and cancer. Nat Rev Cancer.
2:910–917. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Travis LB, Demark Wahnefried W, Allan JM,
Wood ME and Ng AK: Aetiology, genetics and prevention of secondary
neoplasms in adult cancer survivors. Nat Rev Clin Oncol.
10:289–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barcellos-Hoff MH: Does microenvironment
contribute to the etiology of estrogen receptor-negative breast
cancer? Clin Cancer Res. 19:541–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fritz V and Fajas L: Metabolism and
proliferation share common regulatory pathways in cancer cells.
Oncogene. 29:4369–4377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Whitfield ML, George LK, Grant GD and
Perou CM: Common markers of proliferation. Nat Rev Cancer.
6:99–106. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng H, Cheng Y, Guo Z, Zhang F, Lu X,
Feng L, Wang X and Xu Z: Overexpression of CyclinA2 ameliorates
hypoxia-impaired proliferation of cardiomyocytes. Exp Ther Med.
8:1513–1517. 2014.PubMed/NCBI
|
|
22
|
Chen G, Wang H, Xie S, Ma J and Wang G:
STAT1 negatively regulates hepatocellular carcinoma cell
proliferation. Oncol Rep. 29:2303–2310. 2013.PubMed/NCBI
|
|
23
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian Y, Wan H and Tan G: Cell
cycle-related kinase in carcinogenesis. Oncol Lett. 4:601–606.
2012.PubMed/NCBI
|
|
25
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Zhou Q, Zhang N, Li W, Ying M,
Ding W, Yang B and He Q: E2F1 impairs all-trans retinoic
acid-induced osteogenic differentiation of osteosarcoma via
promoting ubiquitination-mediated degradation of RARα. Cell Cycle.
13:1277–1287. 2014. View
Article : Google Scholar :
|
|
27
|
Wang XH, Cai P, Wang MH and Wang Z:
MicroRNA-25 promotes osteosarcoma cell proliferation by targeting
the cell cycle inhibitor p27. Mol Med Rep. 10:855–859.
2014.PubMed/NCBI
|
|
28
|
Dick FA and Rubin SM: Molecular mechanisms
underlying RB protein function. Nat Rev Mol Cell Biol. 14:297–306.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen HZ, Tsai SY and Leone G: Emerging
roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev
Cancer. 9:785–797. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prior IA, Lewis PD and Mattos C: A
comprehensive survey of Ras mutations in cancer. Cancer Res.
72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
|
